Kenvue

Kenvue makes everyday health products like Tylenol and Listerine. These help people manage pain, allergies, and personal care needs. Its brands are used by families, adults, and children worldwide.

Everyday Essentials: What Kenvue Sells

• Self Care (42.3% of revenue): Over-the-counter medicines for pain, allergies, and colds; targets adults and families.
• Skin Health and Beauty (27.4%): Face, body, and hair care products; serves consumers seeking daily skincare and beauty routines.
• Essential Health (30.3%): Oral care, baby care, and wound care; used by families, women, and caregivers.

Growth Moves: Kenvue’s Expansion Playbook

• Spun off from Johnson & Johnson in 2022; became fully independent in 2024.
• Launched initial public offering (IPO) in May 2023 on the New York Stock Exchange.
• Entered over 165 countries by 2024, expanding global reach for all product lines.
• Announced new global headquarters in Summit, New Jersey, opening in 2025.
• Invested in digital transformation and supply chain upgrades starting in 2023.

Why Kenvue Stands Out (Without the Hype)

Kenvue operates a global supply chain, producing most products in-house for flexibility. Its brands are widely recognized and trusted for daily health needs. The company invests in research, digital tools, and sustainability to stay competitive.

Five Things You Need to Know

• Net sales were $15.5 billion in 2024, up 0.1% from 2023.
• Gross profit was $8.96 billion in 2024, up 3.7% year-over-year.
• Operating income fell 26.7% to $1.84 billion in 2024.
• Net income dropped 38.1% to $1.03 billion in 2024.

Bottom Line

Kenvue has evolved from a Johnson & Johnson division to a global health company. Its broad product mix and global reach support steady demand, but recent profits have declined.